Showing results (1-10 of 93) with videos related to
Sort By:
Pageof 10
Expert Opinion on Drug Safety|September 9, 2014
5-Hydroxytryptamine3 receptor antagonists and cardiac side effectsLouise Brygger, Jørn Herrstedt, Expert Opinion on Drug Safety|May 25, 2004
Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomitingJørn HerrstedtNature Clinical Practice. Oncology|December 22, 2007
Antiemetics: an update and the MASCC guidelines applied in clinical practiceJørn HerrstedtUgeskrift for Laeger|March 16, 2007
[Medical treatment of chemotherapy-induced nausea and vomiting]Jørn HerrstedtExpert Review of Anticancer Therapy|February 6, 2010
Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomitingChristina Ruhlmann, Jørn HerrstedtCurrent Opinion in Oncology|June 8, 2021
Teaching supportive care: what is the core curriculum?Jørn Herrstedt, Alex MolassiotisTherapeutics and Clinical Risk Management|June 19, 2009
Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomitingChristina Ruhlmann, Jørn HerrstedtBasic & Clinical Pharmacology & Toxicology|August 19, 2007
Anti-emetic therapy in cancer chemotherapy: current statusJørn Herrstedt, Per DombernowskyCurrent Opinion in Supportive and Palliative Care|August 8, 2008
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapyEva Ellebaek, Jørn HerrstedtPageof 10